dc.contributor.author | Green, Daniel A et al | |
dc.date.accessioned | 2020-05-18T13:39:05Z | |
dc.date.available | 2020-05-18T13:39:05Z | |
dc.date.issued | 2020-05-08 | |
dc.identifier.uri | https://doi.org/10.1101/2020.05.06.20093575 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1521 | |
dc.description.abstract | Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the gold standard for diagnosis of coronavirus disease 2019 (COVID-19), but the test clinical performance is poorly understood. From 3/10/2020-5/1/2020 NewYork-Presbyterian laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338 patients. Repeat testing was performed in 3,432 patients, of which 2,413 had negative and 1,019 had positive first day results. Repeat-tested patients were more likely to be older, male, African-American or Hispanic, and to have severe disease. Among the patients with initially negative results, 18.6% became positive upon repeat-testing. Only 58.1% of any-time positive patients had a result of "detected" on the first test. The clinical sensitivity of COVID-19 molecular assays is estimated between 66.2% and 95.6%, depending on the unknown number of false negative results in single-tested patients. Conversion to a negative result is unlikely to occur before 15 to 20 days after initial testing or 20-30 days after the onset of symptoms, with 50% conversion occurring at 28 days after initial testing. Forty-nine initially-positive patients converted to negative and then back to positive in subsequent days. Conversion from first day negative to positive results increased linearly with each day of testing, reaching 25% probability in 20 days. In summary, our study provides estimates of the clinical performance of SARS-CoV-2 molecular assays and suggests time frames for appropriate repeat testing, namely 15 to 20 days after a positive test and the same or next 2 days after a negative test in a patient with high suspicion for COVID-19. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | SARS-CoV | en_US |
dc.subject | Efficiency | en_US |
dc.subject | Clinical Laboratory Techniques | en_US |
dc.subject | African Americans | en_US |
dc.subject | Hispanic Americans | en_US |
dc.title | Clinical Performance of SARS-CoV-2 Molecular Testing | en_US |
eihealth.country | Regional, Americas (PAHO/OPS) | en_US |
eihealth.category | Virus: natural history, transmission and diagnostics | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
dc.relation.ispartofjournal | medRxiv | en_US |